Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay / Avaliação Mutagênica de Fluoxetina e Complexo Fluoxetina-Galactomanana Através da Análise de Aberrações Cromossômicas em Leucócitos Periféricos Humanos e em Salmonella typhimurium / Ensaio Microssômico
Cavalcanti, Bruno Coêlho; Silva, Cecília Rocha da; Andrade Neto, João Batista de; Josino, Maria Aparecida Alexandre; Sá, Lívia Gurgel do Amaral Valente; Silva, Antônio Adailson de Sousa; Barreto, Francisco Stefânio; Ferreira, José Roberto de Oliveira; Magalhães, Hemerson Iury Ferreira; Vieira, Ícaro Gusmão Pinto; Brito, Débora Hellen Almeida; Ricardo, Nágila Maria Pontes Silva; Barroso, Fátima Daiana Dias; Costa, Érica Rayanne Mota da; Nobre Júnior, Hélio Vitoriano; Moraes, Manoel Odorico de.
J. Health Biol. Sci. (Online);
10(1): 1-6, 01/jan./2022. tab
Artículo
en Inglés
| LILACS | ID: biblio-1411461
Objectives:
The purpose of this study was to evaluate the mutagenic potential of fluoxetine and fluoxetine-galactomannan.Methods:
Chromosomal aberration test and Salmonella typhimurium/microsome mutagenicity assay.Results:
The results showed that fluoxetine (250 µg/mL) can cause chromosomal breaks of treated leukocytes and increase the frequency of reversion of the tester strains of S. typhimurium / microsome assay only at the highest concentration (5 mg/mL), while fluoxetine encapsulated in galactomannan did not cause these changes (leukocytes and S. typhimuriums strains).Conclusion:
In summary, fluoxetine showed a mutagenic effect detectable only at high concentrations in both eukaryotic and prokaryotic models. Furthermore, the fluoxetine/galactomannan complex, in this first moment, prevented the mutagenicity attributed to fluoxetine, emphasizing that the present encapsulation process can be an alternative in preventing these effects in vitro.
Biblioteca responsable:
BR1780.2
Texto completo